Preface.

Foreword.

Part I: Gastroesophageal Cancer: Edited by Richard Sampliner (University of Arizona College of Medicine).

1 Epidemiology of Gastroesophageal Cancer: Evan S. Dellon (University of North Carolina School of Medicine) & Nicholas J. Shaheen (University of North Carolina School of Medicine).

2 Factors involved in Carcinogenesis and Prevention: Mark R. Anderson (City Hospital, Birmingham) & Janusz Jankowski (University of Oxford).

3 Molecular Biology of Gastroesophageal Cancers: the Role of Mutational Analysis in Prognosis: Matthew Lovell (St Bartholomew’s and the London School of Medicine and Dentistry), Chetan Bhan (Eastbourne Hospital), Janusz Jankowski & Stuart McDonald (University of Oxford).

4 Esophageal Adenocarcinoma: Edited by Kenneth K. Wang (Department of Gastroenterology and Hepatology, Rochester, USA).

Diagnosis:.

Endoscopic diagnosis of Barrett’s esophagus: Vidu B. Mokkala (Mayo Clinic, Rochester, USA), Navtej S. Buttar (Mayo Clinic, Rochester, USA) & Louis M. Wong Kee Song (Mayo Clinic, Rochester, USA).

The histologic diagnosis of Barrett’s esophagus: Thomas C. Smyrk (Mayo Clinic, Rochester, USA) & Navtej S. Buttar (Mayo Clinic, Rochester, USA).

Staging of esophageal cancer: Ananya Das (Mayo Clinic Arizona) & Amitabh Chak (Case Western Reserve University School of Medicine).

Treatment:.

Overview: Kenneth K. Wang (Mayo Clinic, Rochester, USA).

Surgical management of esophageal carcinoma: Daniela Molena (University of Rochester Medical Center, USA), Fernando Herbella (University of Rochester, USA) & Jeffrey H. Peters (University of Rochester, USA).

Chemotherapy for metastatic cancer of the esophagus, gastroesophageal junction, and stomach: Aminah Jatoi (Mayo Clinic, Rochester, USA).

Concurrent radiochemotherapy for esophageal cancer: Zhongxing Liao (The University of Texas M. D. Anderson Cancer Center), Luka Milas (The University of Texas M. D. Anderson Cancer Center), Ritsuko Komaki (Anderson Cancer Center, Houston) & Jaffer Ajani (University of Texas MD Anderson Cancer Center).

Ablation, novel agents, and endoscopic therapy for esophageal dysplasia and carcinoma: Herbert C. Wolfsen (Mayo Clinic College of Medicine, Rochester, USA).

Prognosis and follow-up: Kenneth K. Wang (Mayo Clinic, Rochester, USA).

5 Squamous Cancer of the Esophagus: Edited by Hugh Barr (Gloucestershire Royal Hospital).

Diagnosis:.

History and etiology: Alastair Sammon (Gloucestershire Hospitals NHS Foundation Trust) & Mark Vipond (Gloucestershire Royal NHS Foundation Trust).

Clinical: Alastair Sammon (Gloucestershire Hospitals NHS Foundation Trust) & Mark Vipond (Gloucestershire Royal NHS Foundation Trust).

Histopathology and staging: Salim Anjarwalla (Gloucestershire Royal Hospital), David Hewin (Gloucestershire Royal Hospital) & Neil A. Shepherd (Gloucestershire Royal Hospital).

Imaging and clinical staging: David Hewin (Gloucestershire Royal Hospital), Neil A. Shepherd (Gloucestershire Royal Hospital) & Salim Anjarwalla (Gloucestershire Royal Hospital).

Treatment:.

Overview: Hugh Barr (Gloucestershire Royal Hospital).

Surgery: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (John Radcliffe Hospital, Oxford).

Chemotherapy: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (John Radcliffe Hospital, Oxford).

Radiotherapy: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (John Radcliffe Hospital, Oxford).

Ablation of early cancer: Hugh Barr (Gloucestershire Royal Hospital).

Palliation and endoscopic therapy: Hugh Barr (Gloucestershire Royal Hospital).

Novel agents: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (Royal Marsden Hospital, Surrey).

Prognosis and follow-up: Hugh Barr (Gloucestershire Royal Hospital).

6 Diffuse Gastric Cancer: Edited by Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).

Diagnosis:.

History: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).

Clinical: Annemieke Cats (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital).

Histopathology and molecular pathology: Cen Si (Vrije Universiteit Medical Center, Amsterdam), Nicole C.T. van Grieken (Vrije Universiteit Medical Center, Amsterdam) & Gerrit A. Meijer (Vrije Universiteit Medical Center, Amsterdam).

Imaging and staging of gastric cancer: Regina G.H. Beets-Tan (University Hospital Maastrict) & Cornelius van de Velde (Leiden University Medical Center).

Treatment:.

Overview: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).

Surgery: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).

Chemotherapy: Christopher Jackson (Royal Marsden Hospital, Surrey), Naureen Starling (Royal Marsden Hospital, Surrey) & David Cunningham (Royal Marsden Hospital, Surrey).

Radiotherapy: Edwin P.M. Jansen (The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital) & Marcel Verheij (The Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital).

Novel agents: Annemieke Cats (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital).

Prognosis and follow-up: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).

7 Intestinal Gastric Cancer: Edited by Benjamin C.Y. Wong (University of Hong Kong).

Diagnosis: history, clinical and histopathology: Annie O. O. Chan (Queen Mary Hospital, Hong Kong) & Asif Rashid (MD Anderson Cancer Center, Houston).

Imaging and staging: Annie O.O. Chan (Queen Mary Hospital, Hong Kong) & Benjamin C.Y. Wong (University of Hong Kong).

Treatment: Annie O.O. Chan (Queen Mary Hospital, Hong Kong) & Benjamin C.Y. Wong (University of Hong Kong).

Prognosis and follow-up: Annie O.O. Chan (Queen Mary Hospital, Hong Kong) & Benjamin C.Y. Wong (University of Hong Kong).

8 Small Bowel Tumors: Edited by Nadir Arber (Tel Aviv Medical Center and Tel Aviv University).

Diagnosis:.

Epidemiology: Kerin Adelson (Mount Sinai School of Medicine, New York), Eyal Sagiv (Tel Aviv Medical Center), Nadir Arber (Tel Aviv Medical Center and Tel Aviv University) & Alfred I. Neugut (Columbia University Medical Center, New York).

Endoscopy in the diagnosis of small bowel tumors: Ian M. Gralnek (Rambam Health Care Campus, Israel) & Rami Eliakim (Technion-Israe Institute of Technology, Israel).

Molecular biology of small bowel tumors: Eyal Sagiv (Tel Aviv Medical Center), Kerin Adelson (Mount Sinai School of Medicine, New York), Alfred I. Neugut (Columbia University Medical Center, New York) & Nadir Arber (Tel Aviv Medical Center and Tel Aviv University).

Imaging and staging: Yulia Bronstein (MD Anderson Cancer Center, Houston) & Ronelle Dubrow (MD Anderson Cancer Center, Houston).

Treatment:.

Surgery: Ido Nachmany (Tel Aviv University) & Joseph M. Klausner (Tel Aviv University).

Other treatments: Pascal Peeters (University Hospital Gasthuisberg, Belgium), Eric Van Cutsem (University Hospital Gasthuisberg, Belgium) & Mario Dicato (Luxembourg Medical Center).

9 Sarcoma and Gastrointestinal Stromal Tumors: Edited by Markku Miettinen (Armed Forces Institute of Pathology, Washington).

Introduction: Markku Miettinen (Armed Forces Institute of Pathology, Washington).

Pathology, prognosis and genetics of gastrointestinal stromal tumors (GISTs): Markku Miettinen (Armed Forces Institute of Pathology, Washington) & Jerzy Lasota (Armed Forces Institute of Pathology, Washington).

Imaging and staging of gastrointestinal stromal tumors: Angela D. Levy (Uniformed Services University of the Health Sciences, Maryland).

Treatment: Heikki Joensuu (Helsinki University Central Hospital) & Ronald P. DeMatteo (Memorial Sloan-Kettering Cancer Center, New York).

10 Rare Tumors of the Abdomen: Edited by Anil R. Prasad (University of Arizona Health Sciences Center).

Smooth muscle and pericytic tumors: Mitual Amin (William Beaumont Hospital, USA), Malathy Kapali (University of Arizona), Benjamin Paz (City of Hope National Medical Center, California), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).

Vascular tumors: Mitual Amin (William Beaumont Hospital, USA), Malathy Kapali (University of Arizona), Benjamin Paz (City of Hope National Medical Center, California), John Fetsch (Armed Forces Institute of Pathology, Washington) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).

Adipose tissue tumors: John Fetsch (Armed Forces Institute of Pathology, Washington), Anil R. Prasad (University of Arizona Health Sciences Center), Sanjay Saluja (Yale University School of Medicine) & Benjamin Paz (City of Hope National Medical Center, California).

Neurogenic tumors: Anil R. Prasad (University of Arizona Health Sciences Center), Markku Miettenen (Armed Forces Institute of Pathology, Washington) & Benjamin Paz (City of Hope National Medical Center, California).

Myofibroblastic and fi brous tumors: John Fetsch (Armed Forces Institute of Pathology, Washington), Malathy Kapali (University of Arizona), Benjamin Paz (City of Hope National Medical Center, California), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).

Mesothelial tumors: Anil R. Prasad (University of Arizona Health Sciences Center), Malathy Kapali (University of Arizona), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).

Gastric lymphomas: Anil R. Prasad (University of Arizona Health Sciences Center), Sanjay Saluja (Yale University School of Medicine) & Daniel O. Persky (University of Arizona Health Sciences Center).

Rare miscellaneous tumors and tumor-like lesions: Anil R. Prasad (University of Arizona Health Sciences Center), John Fetsch (Armed Forces Institute of Pathology, Washington), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).

Part II: Colorectal Cancer: Edited by David Kerr (University of Oxford).

11 Epidemiology and Prevention of Colorectal Cancer: Paul Moayyedi (McMaster University Medical Centre, Canada).

12 The Molecular Pathology of Sporadic and Hereditary Colorectal Cancer: Massimo Pignatelli (Bristol Royal Infirmary), Nahida Banu (Bristol Royal Infirmary) & Zsombor Melegh (Bristol Royal Infirmary).

13 Screening for Colorectal Cancer: Robert J.C. Steele (Ninewells Hospital and Medical School, Dundee).

14 Cancer of the Colon and Rectum: Edited by Rachel S. Midgley (University of Oxford).

Diagnosis:.

Clinical presentation: Omar Khan (Churchill Hospital, Oxford), Rachel S. Midgley (University of Oxford) & Andrew Weaver (John Radcliffe Hospital, Oxford).

Histopathology: Daniel Royston (John Radcliffe Hospital, Oxford) & Bryan Warren (John Radcliffe Hospital, Oxford).

Imaging and staging: Margaret Betts (John Radcliffe Hospital, Oxford).

Treatment:.

Overview of therapy modalities: Rachel S. Midgley (University of Oxford).

Surgery: Baljit Singh (John Radcliffe Hospital, Oxford) & Chris Cunningham (John Radcliffe Hospital, Oxford).

Chemotherapy: Ami Sabharwal (University of Oxford) & David Kerr (University of Oxford).

Radiotherapy for rectal cancer: Robert Glynne-Jones (Mount Vernon Cancer Centre).

Surgery for liver metastases: Zahir Soonwalla (John Radcliffe Hospital, Oxford).

Ablative treatments: Fergus Gleeson (The Churchill Hospital, Oxford).

Novel therapies: Carlos Escriu (Clatterbridge Centre for Oncology, Liverpool), Mark Middleton (Churchill Hospital, Oxford) & Rachel S. Midgley (University of Oxford).

Stomas: Ann MacArthur (Oxford Radcliffe Hospitals NHS Trust) & Julia Liddi (John Radcliffe Hospital, Oxford).

Answers to case scenerios: Omar Khan (Churchill Hospital, Oxford), Rachel S. Midgley (University of Oxford) & Andrew Weaver (John Radcliffe Hospital, Oxford).

15 Rare Cancers: Edited by Colin McArdle (Royal Infirmary, Glasgow).

Gastrointestinal carcinoids: Irwin M. Modlin (Yale University School of Medicine), Jon Bornschein (Yale University School of Medicine) & Mark Kidd (Yale University School of Medicine).

Anorectal melanoma: Gary N. Mann (University of Washington Medical Center), Shailender Bhatia (University of Washington) & John L. Thompson (University of Washington).

Cancer of the anal canal: Matthew Clark (University of Auckland) & Lincoln Israel (Middlemore Hospital, Auckland).

Appendiceal epithelial neoplasms: Paul H. Sugarbaker (Washington Hospital Center).

Diffuse malignant peritoneal mesothelioma: Tristan D. Yan (Washington Hospital Center) & Paul H. Sugarbaker (Washington Hospital Center).

Part III: Hepatobiliary Cancer: Edited by Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).

16 Epidemiology of Hepatocellular Carcinoma: Hashem B. El-Serag (College of Medicine, Houston), Donna L. White (Baylor College of Medicine, Houston) & Zhannat Nurgalieva (Baylor College of Medicine, Houston).

17 Factors involved in Carcinogenesis and Prevention in Hepatobiliary Cancer: Paula Ghaneh (University of Liverpool), William Greenhalf (University of Liverpool) & John P. Neoptolemos (University of Liverpool).

18 Molecular Biology of Hepatobiliary Cancer: Knut Ketterer (Technical University of Munich) & Helmut Friess (Technical University of Munich).

19 Primary Liver Cancer: Edited by Charlie Pan (University of Michigan Medical School) & Theodore Lawrence (University of Michigan).

Diagnosis:.

History and clinical: Jorge A. Marrerro (University of Michigan) & Charlie Pan (University of Michigan Medical School).

Histopathology: Rebecca F. Harrison (Leicester General Hospital) & Angus H. McGregor (Leicester Royal Infirmary).

Imaging and staging: Jonathon Willatt (University of Michigan) & Hero K. Hussain (University of Michigan Health System).

Treatment:.

Overview: Charlie Pan (University of Michigan Medical School).

Surgery: Shawn J. Pelletier (University of Michigan Health System) & James A. Knol (University of Michigan Department of Surgery).

Ablation: James A. Knol (University of Michigan Department of Surgery).

Radiotherapy: Charlie Pan (University of Michigan Medical School) & Theodore Lawrence (University of Michigan).

Chemotherapy: Charlie Pan (University of Michigan Medical School) & William D. Ensminger (Upjohn Center SPC 5504, USA).

Novel agents: Charlie Pan (University of Michigan Medical School) & William D. Ensminger (Upjohn Center SPC 5504, USA).

Prognosis and follow-up: Charlie Pan (University of Michigan Medical School).

20 Metastatic Liver Cancer: Edited by Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).

Treatment:.

Overview: Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).

Surgical therapy for hepatic colorectal metastases: Darren Carpizo (Memorial Sloan-Kettering Cancer Center, New York) & Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).

Systemic chemotherapy: Nancy Kemeny (Memorial Sloan-Kettering Cancer Center, New York).

Ablative Therapy: Anne M. Covey (Memorial Sloan-Kettering Cancer Center, New York).

Radiation therapy: Christopher Willet (Duke University Medical Center, USA) & Brian G. Czito (Duke University Medical Center, USA).

21 Primary Pancreatic Adenocarcinoma: Edited by Christopher L. Wolfgang (Johns Hopkins Hospital, USA).

Diagnosis:.

Epidemiology, history and clinical fi ndings: Timothy M. Pawlik (Johns Hopkins School of Medicine, USA).

Histopathology: Ralph H. Hruban (The Johns Hopkins Medical Institutions, USA).

CT imaging in pancreatic cancer: Karen M. Horton (Johns Hopkins Medical Institutions, USA) & Elliot K. Fishman (Johns Hopkins Hospital, USA).

Treatment:.

Overview: Christopher L. Wolfgang (Johns Hopkins Hospital, USA).

Surgery: Robert A. Meguid (Johns Hopkins University School of Medicine, USA) & Christopher L. Wolfgang (Johns Hopkins Hospital, USA).

Chemotherapy: Daniel Laheru (The Johns Hopkins University School of Medicine, USA).

Radiotherapy: Joseph Herman (The Johns Hopkins University, USA).

Novel agents: Manuel Hildago (The Johns Hopkins University School of Medicine, USA).

Prognosis and follow-up: Jeffrey Infante (Sarah Cannon Research Institute, USA) & Wells Messersmith (University of Colorado).

22 Cholangiocarcinoma: Edited by Ravi S. Chari (Vanderbilt University Medical Center, USA).

Diagnosis:.

Overview: Ravi S. Chari (Vanderbilt University Medical Center, USA).

History: T. Markley Earl (Vanderbilt University School of Medicine, USA), Burnett S. Kelly (Vanderbilt University Medical Center, USA) & Ravi S. Chari (Vanderbilt University Medical Center, USA).

Clinical: T. Markley Earl (Vanderbilt University School of Medicine, USA), Burnett S. Kelly (Vanderbilt University Medical Center, USA) & Ravi S. Chari (Vanderbilt University Medical Center, USA).

Histopathology: Elizabeth I. Johnston (Vanderbilt University School of Medicine, USA) & Mary Kay Washington (Vanderbilt University Medical Center, USA).

Imaging and Staging: Christopher D. Anderson (Washington University in St. Louis), T. Markley Earl (Vanderbilt University School of Medicine, USA), Stephen J. Meranze (Vanderbilt University Medical Center, USA) & Ravi S. Chari (Vanderbilt University Medical Center, USA).

Treatment:.

Overview: Ravi S.Chari (Vanderbilt University Medical Center, USA).

Surgery: Christopher D. Anderson (Washington University in St. Louis) & Ravi S. Chari (Vanderbilt University Medical Center, USA).

Chemotherapy: Laura A. Williams (Vanderbilt University, USA) & Jordan Berlin (Vanderbilt University, USA).

Role of radiation therapy: Jayamarx Jayaraman (Vanderbilt University Medical Center, USA) & A. Bapsi Chakravarthy (Vanderbilt University Medical Center, USA).

Ablation: Christopher D. Anderson (Washington University in St. Louis) & Ravi S. Chari (Vanderbilt University Medical Center, USA).

Prognosis and follow-up: Christopher D. Anderson (Washington University in St. Louis) & Ravi S. Chari (Vanderbilt University Medical Center, USA).

23 Neuroendocrine Tumors: Edited by Ursula Plöckinger (Charité-Universitätsmedizin Berlin).

History and histopathology: Guido Rindi (University of Parma) & Cesare Bordi (Universita Degli Studi di Parma).

Diagnosis, staging, prognosis and follow-up:.

Gastric neuroendocrine tumors: Gianfranco Delle Fave (Università di Roma ‘La Sapienza’).

Gastrinoma: Frédérique Maire (Hôpital Beaujon, Clichy) & Phillippe Ruszniewski (Université Denis Diderot, Paris).

Insulinoma: Wouter W. de Herder (Erasmus MC, Rotterdam).

Non-functioning endocrine tumors of the pancreas: Dimitios Papdogias (General Hospital ‘G. Gennimatas’, Athens) & Gregory Kaltsas (National University of Athens).

Rare functioning pancreatic endocrine tumors: Dermot O’Toole (St James’s Hospital and Trinity College Dublin).

Midgut and appendiceal tumors: Barbro Eriksson (Uppsala University Hospital).

Neuroendocrine tumors of the colon and rectum: Christoph J. Auernhammer (Klinikum der Ludwig-Maximilians-Universität, München).

Imaging of gastroenteropancreatic neuroendocrine tumors: Anders Sundin (Karolinska University Hospital Solna, Stockholm).

Treatment:.

Overview: Rudolf Arnold (University, Marburg) & Anja Rinke (Philipps Universität Marburg).

Surgery: pancreatic tumors: Göran Åkerström (University Hospital, Uppsala) & Per Hellman (University Hospital, Uppsala).

Surgery: midgut tumors: Matthias Rothmund (Philipps Universität Marburg).

Surgery: liver metastases: Håkan Ahlman (University of Göteborg, Sweden) & Michael Olausson (University of Göteborg, Sweden).

Ablative therapy: Massimo Falconi (Policlinico ‘GB Rossi’, Veroni) & Rossella Bettini (Gastroenterologiche Policlinico ‘GB Rossi’, Verona).

Radiolabeled somatostatin analogs: Dik J. Kwekkeboom (University Hospital Rotterdam), Jaap J.M. Teunissen (University Hospital Rotterdam), Boen L. Kam (Erasmus MC, Rotterdam), Roelf Valkema (Erasmus MC, Rotterdam), Wouter W. de Herder (Erasmus MC, Rotterdam) & Eric P. Krenning (Erasmus MC, Rotterdam).

Biotherapy and chemotherapy: Ursula Plöckinger (Charité-Universitätsmedizin Berlin).

Novel agents: Marianne Pavel (Universitätsklinikum Ulmenweg, Erlangen).

24 Rare Tumors of the Liver: Shantanu Battacharjya (BGS Global Hospital, Bangalore), Zahir Soonawalla (John Radcliffe Hospital), Rachel R. Phillips (University of Oxford) & Peter J. Friend (University of Oxford).

25 Cystic Neoplasms of the Pancreas: Edited by Peter J. Allen (Memorial Sloan-Kettering Cancer Center, New York).

Diagnosis and imaging: John Mansour (Memorial Sloan-Kettering Cancer Center, New York) & Lawrence Schwartz (Memorial Sloan-Kettering Cancer Center, New York).

Treatment recommendations: John Mansour (Memorial Sloan-Kettering Cancer Center, New York) & Peter J. Allen (Memorial Sloan-Kettering Cancer Center, New York).

Endoscopic assessment and treatment: Mark Greaves (Memorial Sloan-Kettering Cancer Center, New York) & Mark Schattner (Memorial Sloan-Kettering Cancer Center, New York).

Index